<DOC>
	<DOCNO>NCT01796171</DOCNO>
	<brief_summary>This study phase I/II , open-label study patient relapse positive non-Hodgkin lymphoma . The Phase I part study dose escalate study define maximum tolerable dose 177Lu-DOTA-HH1 ( Betalutin ) , assess safety toxicity , pharmacokinetics , biodistribution efficacy . After completion phase I study , dose select phase II part study design investigate tumour response rate , progression free survival , confirmation select dose well safety toxicity .</brief_summary>
	<brief_title>A Phase I/II Study Betalutin Treatment Relapsed Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Histologically confirm ( WHO classification ) relapse incurable nonHodgkin Bcell lymphoma follow subtypes ; follicular grade IIIIA , marginal zone , small lymphocytic , lymphoplasmacytic , mantle cell . 2 . Age ≥ 18 year 3 . A prestudy WHO performance status 01 4 . Life expectancy ≥ 3 month 5 . &lt; 25 % tumour cell bone marrow biopsy 6 . Measurable disease radiological method 7 . Women childbearing potential must : 1. understand study medication expect teratogenic risk 2. negative pregnancy test 3. agree use , able comply , effective contraception without interruption , 4 week start study drug , throughout study drug therapy 12 month end study drug therapy , even amenorrhoea 8 . Male subject must agree use condom intercourse throughout study drug therapy follow 12 month 9 . Patients previously treat native rituximab eligible 10 . The patient willing able comply protocol , agree return hospital followup visit examination 11 . The patient fully inform study sign informed consent form 1 . Medical contraindication , include uncontrolled infection , severe cardiac , pulmonary , neurologic , psychiatric metabolic disease , steroid require asthma/allergy , know HIV positive 2 . Laboratory value within 15 day preregistration : 1 . Absolute Neutrophil Counts ( ANC ) ≤ 1.5 x 109 /l 2 . Platelet count ≤ 150 x 109 /l 3 . Total bilirubin ≥ 30 mmol/l 4 . ALP ALAT ≥ 4x normal level ) 5 . Creatinine ≥ 115 µmol/l ( men ) , 97 µmol/l ( woman ) ) 6 . IgG ≤ 3 gr/l 3 . Known CNS involvement lymphoma 4 . Previous total body irradiation , irradiation &gt; 25 % patient 's bone marrow 5 . Known history HAMA 6 . Chemotherapy immunotherapy receive within last 4 week prior start study treatment . Pretreatment rituximab allow 7 . Pregnant lactate woman 8 . Previous hematopoietic stem cell transplantation ( autologous allogenic ) 9 . Previous treatment radioimmunotherapy 10 . Actively participate another study receive investigational drug within 4 week prior enrolment 11 . Receipt live , attenuated vaccine within 30 day prior enrolment 12 . Test positive hepatitis B ( HBsAg antiHBc ) 13 . A known hypersensitivity rituximab , HH1 , Betalutin murine proteins excipient use rituximab , HH1 Betalutin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Lu-177</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Phase II study</keyword>
	<keyword>Betalutin</keyword>
</DOC>